810 related articles for article (PubMed ID: 8388318)
41. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Raynaud FI; Mistry P; Donaghue A; Poon GK; Kelland LR; Barnard CF; Murrer BA; Harrap KR
Cancer Chemother Pharmacol; 1996; 38(2):155-62. PubMed ID: 8616906
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
43. [The prospect for cisplatin analogs from the experimental standpoint].
Tashiro T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1358-65. PubMed ID: 2543305
[TBL] [Abstract][Full Text] [Related]
44. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
45. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
46. Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.
Harrap KR
Cancer Res; 1995 Jul; 55(13):2761-8. PubMed ID: 7796401
[TBL] [Abstract][Full Text] [Related]
47. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note.
Goddard PM; Valenti MR; Harrap KR
Ann Oncol; 1991 Sep; 2(8):535-40. PubMed ID: 1793720
[TBL] [Abstract][Full Text] [Related]
48. Cytotoxicity of 2,2':6',2' '-terpyridineplatinum(II) complexes against human ovarian carcinoma.
Lowe G; Droz AS; Vilaivan T; Weaver GW; Park JJ; Pratt JM; Tweedale L; Kelland LR
J Med Chem; 1999 Aug; 42(16):3167-74. PubMed ID: 10447962
[TBL] [Abstract][Full Text] [Related]
49. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
50. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
51. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
52. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
53. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
54. Cytotoxic activity of [Pt(pyr)(N-Etlm)Cl4].
Massacesi M; Matovic Z; Ponticelli G
Farmaco; 1993 Sep; 48(9):1327-30. PubMed ID: 8259989
[TBL] [Abstract][Full Text] [Related]
55. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
56. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
57. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
58. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
Jones M; Siracky J; Kelland LR; Harrap KR
Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
[TBL] [Abstract][Full Text] [Related]
59. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
Zák F; Turánek J; Kroutil A; Sova P; Mistr A; Poulová A; Mikolin P; Zák Z; Kasná A; Záluská D; Neca J; Sindlerová L; Kozubík A
J Med Chem; 2004 Jan; 47(3):761-3. PubMed ID: 14736257
[TBL] [Abstract][Full Text] [Related]
60. Cytotoxicity of tetraplatin and cisplatin for human and rodent cell lines cultured as monolayers and multicellular spheroids.
Bhuyan BK; Folz SJ; DeZwaan J; Northcott SE; Alberts DS; Garcia D; Wallace TL; Li LH
Cancer Commun; 1991 Feb; 3(2):53-9. PubMed ID: 1995028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
